ScreenerHero

KRSA Korsana Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · korsana.com
30.07USD-6.29%Mkt Cap: 1.37B $P/E: —

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$131.98BUSDP/E 30.3
REGN
Regeneron Pharmaceuticals, Inc.
$84.02BUSDP/E 20.2
MRNA
Moderna, Inc.
$83.03BUSD
CSL
CSL Limited
$66.33BUSD
UCB
UCB SA
$57.32BUSDP/E 23.7
ARGX
argenx SE
$55.50BUSDP/E 30.6
ARGX
argenx SE
$55.08BUSDP/E 31.5
ONC
BeOne Medicines AG
$41.65BUSDP/E 65.5
RVMD
Revolution Medicines, Inc.
$39.91BUSD
RPRX
Royalty Pharma plc
$37.72BUSDP/E 34.7
ALNY
Alnylam Pharmaceuticals, Inc.
$30.35BUSDP/E 38.2
GMAB
Genmab A/S
$27.58BUSDP/E 37.0
GMAB
Genmab A/S
$27.47BUSDP/E 35.2
ROIV
Roivant Sciences Ltd.
$26.39BUSD
INCY
Incyte Corporation
$23.63BUSDP/E 14.9
BNTX
BioNTech SE
$21.87BUSD
INSM
Insmed Incorporated
$20.74BUSD
EXEL
Exelixis, Inc.
$16.19BUSDP/E 20.6
ASND
Ascendis Pharma A/S
$16.18BUSDP/E 18.8
HALO
Halozyme Therapeutics, Inc.
$14.58BUSDP/E 37.6
Institutional holders20 on file

Key Statistics

Company
Market Cap1.37B USD
Enterprise Value235.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-35.64M USD
Revenue/Share—
Last Price30.07 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.46
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-3.84
EPS (TTM)-7.07
EPS (Forward)-3.56
52W Range
7.18944% of range59.36
52W High59.36 USD
52W Low7.189 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE104.93%
ROA-23.05%
ROIC—
ROCE-26.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.41M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-133.06M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.85
Current Ratio17.40
Quick Ratio17.28
Book Value/Sh-7.84 USD
Cash/Share22.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateSep 9, 2026
Analyst Consensus
Rating—
Target (Mean)44.00 USD
Upside (mean)+46.3%
Target Range8.000 USD – 70.00 USD
8.000+46.3% to mean70.00
# Analysts5
Ownership
Shares Out.45.54M
Float4.31M
Insiders6.64%
Institutions45.26%
Short Interest
Short Ratio0.1d
Short % Out.0.03%
Shares Short11.55K
Technical
SMA 5030.85 (-2.5%)
SMA 20021.48 (+40.0%)
Beta1.73
S&P 52W Chg10.89%
Avg Vol (30d)121.87K
Avg Vol (10d)178.91K
Technical Indicators
RSI (14)45.7
MACD0.1649
MACD Signal0.5238
MACD Hist.-0.3589
BB Upper34.70 USD
BB Middle32.16 USD
BB Lower29.62 USD
BB Width15.77%
ATR (14)2.949 USD
Vol Ratio (20d)1.44x